X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
By utilizing MRI’s internal pro-forma revenue projections for 2023 & 2024 and comparable market transactions, MRI’s drug development pipeline including MAN-01 and companion diagnostics, are estimated to achieve a net present value.
Lead Product(s): MAN-01
Therapeutic Area: Ophthalmology Product Name: MAN-01
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Q BioMed
Deal Size: $42.3 million Upfront Cash: Undisclosed
Deal Type: Agreement November 14, 2022
Details:
MAN-19 therapeutic is a recombinant fusion protein that treats the patient, instead of targeting the virus. It is not a cure for COVID, but it strengthens a patient's blood vessels and protects them against ARDS, breathing problems, sepsis and other infections.
Lead Product(s): MAN-19
Therapeutic Area: Infections and Infectious Diseases Product Name: MAN-19
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Q BioMed
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2021
Details:
Platform has been awarded grants from Canada and Europe for its development of therapeutics; additional grant submitted to the STTR program administered by the U.S. National Institutes of Health.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
